For example, a phase II trial in metastatic melanoma patients has shown that compared with ipilimumab (CTLA-4 blockade) monotherapy, the combination of ipilimumab and GM-CSF resulted in enhanced overall survival rate and tumor reduction with less toxicity [155]. The gene discussed is CTLA4; the disease is neoplasm.